LRMR Larimar Therapeutics, Inc.

CIK 0001374690 50 ready 8-Ks latest August 4, 2026, 7:02 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 4, 2026, 7:02 AM ET

Top materiality 0.85

Event mix other_material ×23 · earnings ×10 · regulatory ×7

Sentiment 21 pos · 1 neg · 28 neu

Latest earnings ▼ miss 2025-Q3

Executive change recent →

Recent 8-K filings for LRMR

Highest-materiality recent filing

Larimar submits BLA module for nomlabofusp accelerated approval; positive open-label data in Friedreich's ataxia

June 29, 2026, 6:33 AM ET regulatory materiality 0.85 positive item 8.01 item 9.01

Submitted first module of rolling BLA to FDA for accelerated approval of nomlabofusp; FDA confirmed existing data appears sufficient.
Open-label study: 100% (9/9) of participants achieved skin FXN levels >50% of healthy volunteer mean at 1 year.

Read filing →

August 4, 2026, 7:02 AM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

Larimar Q2 net loss $32.8M; nomlabofusp BLA rolling submission underway

Net loss $32.8M ($0.30/sh) vs $26.2M ($0.41/sh) in Q2 2025; cash $156.3M, runway into Q3 2027.
June 29, 2026, 6:33 AM ET regulatory materiality 0.85 positive item 8.01 item 9.01

Larimar submits BLA module for nomlabofusp accelerated approval; positive open-label data in Friedreich's ataxia

Submitted first module of rolling BLA to FDA for accelerated approval of nomlabofusp; FDA confirmed existing data appears sufficient.
May 19, 2026, 4:27 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×6

Larimar shareholders approve increase in authorized shares to 215M; reelect three directors

Shareholders approved amendment increasing authorized common shares from 115M to 215M (89.7M for, 1.05M against).
May 14, 2026, 7:02 AM ET other material materiality 0.85 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M

Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.
March 19, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Larimar reports Q4 net loss $62.5M; BLA for nomlabofusp on track for June 2026 submission

Net loss Q4 2025 $62.5M ($0.73/sh) vs $28.8M ($0.45/sh) in Q4 2024; R&D expenses rose to $59.4M.
March 9, 2026, 7:59 PM ET other material materiality 0.10 neutral item 8.01 item 9.01

Larimar Therapeutics posts updated corporate presentation; no material news disclosed

Company made updated corporate slide presentation available on its website on March 9, 2026.
February 27, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements

Larimar Therapeutics prices 20M share public offering at $5.00 per share; underwriters exercise over-allotment

Offering of 20,000,000 shares plus 3,000,000 over-allotment shares at $5.00 per share.
February 24, 2026, 6:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Larimar Therapeutics receives FDA Breakthrough Therapy Designation for nomlabofusp in Friedreich's ataxia

FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich's ataxia.
January 22, 2026, 6:59 PM ET other material materiality 0.50 neutral item 3.02 item 5.03 item 9.01 ◈ Equity Issuances

Larimar Therapeutics exchanges 2.5M common shares for Series A convertible preferred with Blue Owl

Blue Owl Healthcare exchanged 2,500,000 common shares for 250,000 Series A convertible preferred shares (10:1 conversion ratio).
January 12, 2026, 6:59 PM ET other material materiality 0.50 neutral item 2.02 item 8.01 item 9.01

Larimar Therapeutics reports preliminary cash position of $136.9M as of Dec 31, 2025

Preliminary cash, cash equivalents and marketable securities of $136.9M as of Dec 31, 2025, unaudited.
December 17, 2025, 6:59 PM ET other material materiality 0.55 neutral item 3.02 item 5.03 item 9.01 ◈ Equity Issuances

Larimar exchanges 2.5M common shares for 250K convertible preferred with Blue Owl

Blue Owl Healthcare exchanged 2,500,000 common shares for 250,000 Series A convertible preferred shares.
November 10, 2025, 6:59 PM ET other materiality 0.05 neutral item 8.01 item 9.01

Larimar posts corporate deck; no material new facts in filed excerpt

Larimar posted an updated corporate presentation on its website on November 10, 2025.
November 5, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Larimar Therapeutics Q3 2025: Net loss $47.7M, nomlabofusp shows 100% FXN level in OL study

Net loss for Q3 2025 was $47.7M ($0.61 per share) vs $15.5M in Q3 2024, with R&D expenses up to $44.9M.
October 14, 2025, 7:59 PM ET other material materiality 0.10 neutral item 8.01 item 9.01

Larimar posts updated corporate presentation; no financial or clinical data in filing

The 8-K filed on Oct 14, 2025, indicates an updated slide deck was posted on the company website.
September 29, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01 item 9.01

Larimar reports positive nomlabofusp data; all 6-month patients reach carrier-level FXN

10/10 participants at 6 months achieved skin FXN >50% of healthy volunteer median (asymptomatic carrier levels).
August 14, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 8.01 item 9.01

Larimar Therapeutics reports Q2 2025 net loss $26.2M; BLA for nomlabofusp on track for Q2 2026

Net loss $26.2M ($0.41/share) vs $21.6M ($0.34) in Q2 2024; R&D expenses $23.4M, up from $19.7M.
July 31, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 9.01

Larimar Therapeutics prices $64.4M common stock offering at $3.20 per share

Offering of 18,750,000 shares of common stock at $3.20; underwriters' over-allotment of 2,812,500 shares exercised in full.
July 29, 2025, 7:59 PM ET other material materiality 0.50 neutral item 2.02

Larimar Therapeutics reports preliminary cash balance of $138.5M as of June 30, 2025

Preliminary unaudited cash, cash equivalents and marketable securities of $138.5M as of June 30, 2025.
June 23, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Larimar gets FDA safety database guidance; nomlabofusp BLA submission planned for Q2 2026

FDA recommends safety database of ≥30 participants with 6-month continuous exposure (≥10 with 1-year), majority on 50 mg dose.
June 23, 2025, 7:59 PM ET other material materiality 0.10 neutral item 8.01 item 9.01

Larimar posts updated corporate presentation for investor meetings

Company posted updated slide presentation on June 23, 2025 for use in meetings with investors and analysts.
May 13, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

Larimar Therapeutics holds 2025 Annual Meeting; all proposals pass

Thomas E. Hamilton elected Class II director with 46.5M votes for, 4.3M withheld.
May 5, 2025, 7:59 PM ET other materiality 0.15 neutral item 8.01 item 9.01

Larimar posts updated corporate presentation; no material new data

Updated slide deck dated May 5, 2025 posted on company website.
April 30, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Larimar Q1 net loss $29.3M; FDA open to accelerated approval using skin FXN as surrogate endpoint

Net loss $29.3M ($0.46 per share) vs $14.7M ($0.27) YoY; R&D spend rose to $26.6M on manufacturing and Phase 3 prep.
March 24, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 2.02 item 8.01 item 9.01

Larimar reports FDA open to FXN as surrogate endpoint; BLA submission on track for end-2025

FDA considers skin FXN concentration reasonably likely surrogate endpoint for accelerated approval of nomlabofusp in Friedreich's ataxia.
January 27, 2025, 6:59 PM ET other materiality 0.25 neutral item 5.02 item 9.01

Larimar grants performance-based PSUs to four top executives

CEO Carole Ben-Maimon receives 100,000 PSUs tied to regulatory milestones.
January 10, 2025, 6:59 PM ET other materiality 0.15 neutral item 8.01 item 9.01

Larimar Therapeutics posts updated corporate presentation on website

Company filed an 8-K announcing an updated slide presentation posted on January 10, 2025.
December 16, 2024, 6:59 PM ET other material materiality 0.80 positive item 8.01 item 9.01

Larimar reports positive OLE data: FXN up to 30% of healthy in buccal cells at Day 90; BLA filing targeted 2H 2025

Mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90.
November 18, 2024, 6:59 PM ET other material materiality 0.15 neutral item 8.01 item 9.01

Larimar Therapeutics posts corporate slide presentation; no material facts visible from truncated exhibit

Filed 8-K on Nov 18, 2024, attaching a corporate presentation (Exhibit 99.1).
October 30, 2024, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 8.01 item 9.01

Larimar reports Q3 2024 net loss of $15.5M; cash $203.7M, BLA target 2H 2025

Net loss of $15.5M ($0.24 per share) vs $9.1M loss ($0.21 per share) in Q3 2023.
August 7, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 8.01 item 9.01

Larimar Q2 net loss $21.6M; cash $226.1M; OLE interim data Q4; FDA START program

Net loss $21.6M ($0.34/sh) vs $8.4M loss in Q2 2023; R&D spend $19.7M up from $5.9M on manufacturing.
June 10, 2024, 7:59 PM ET other material materiality 0.20 neutral item 8.01 item 9.01

Larimar posts updated corporate presentation; no specific changes disclosed

Company posted updated slide presentation on its website on June 10, 2024.
May 31, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

Larimar Therapeutics shareholders elect Class I directors, approve all proposals at 2024 annual meeting

Jonathan Leff and Jeffrey Sherman re-elected as Class I directors with ~40.7M and ~51.1M votes for, respectively.
May 30, 2024, 7:59 PM ET regulatory materiality 0.50 positive item 8.01 item 9.01

FDA selects Larimar's nomlabofusp for START pilot program to accelerate FA development

FDA selects nomlabofusp for START pilot program based on potential clinical benefit and program readiness.
May 20, 2024, 7:59 PM ET regulatory materiality 0.80 positive item 8.01 item 9.01

FDA removes partial clinical hold on Larimar's nomlabofusp for Friedreich's Ataxia

FDA cleared Phase 2 data review; nomlabofusp generally well-tolerated with dose-dependent frataxin increases.
May 9, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Larimar Q1 net loss $14.7M; cash $239M; nomlabofusp Phase 2 positive; OLE dosed; BLA target 2H 2025

Net loss $14.7M ($0.27/shr) vs $6.5M in Q1 2023; R&D expenses rose to $12.9M on manufacturing and clinical costs.
March 14, 2024, 7:59 PM ET other material materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Larimar reports positive Phase 2 data for nomlabofusp; $161.6M financing extends runway into 2026

Phase 2 dose exploration study met endpoints: dose-dependent frataxin increases in skin and buccal cells; 50 mg cohort saw levels >33% of healthy volunteers in all patients at Day 14.
March 11, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Larimar doses first patient in open-label extension study of nomlabofusp for Friedreich's ataxia

First patient dosed in OLE evaluating 25 mg daily subcutaneous nomlabofusp for Friedreich's ataxia.
February 16, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 9.01 ◈ Material Agreements

Larimar Therapeutics closes $161.8M public offering of 19.7M shares at $8.74

Offered 17,162,472 shares plus 2,574,370 option shares exercised immediately.
February 14, 2024, 6:59 PM ET other materiality 0.20 neutral item 1.02 ◈ Material Agreements

Larimar Therapeutics terminates at-the-market equity facility with Guggenheim; no shares ever sold

Terminated Sales Agreement with Guggenheim Securities effective Feb 13, 2024.
February 12, 2024, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 8.01 item 9.01

Larimar reports positive Phase 2 nomlabofusp data; frataxin dose response up to 5.57 pg/µg in skin

50 mg cohort: median FXN increase in skin 5.57 pg/µg at day 14; all patients reached >33% healthy volunteer level.
November 14, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Larimar completes Phase 2 50mg cohort enrollment; top-line data now Q1 2024; cash to Q1 2025

Completed enrollment and dosing of 50 mg cohort in Phase 2 FA trial; no serious adverse events observed (blinded).
October 3, 2023, 7:59 PM ET leadership materiality 0.50 positive item 5.02 ◈ executive_change

Larimar Therapeutics appoints Dr. Jeffrey W. Sherman to Board of Directors

Board expanded from 5 to 6 members; Dr. Sherman appointed as Class I director through 2024 annual meeting.
August 14, 2023, 7:59 PM ET other material materiality 0.25 neutral item 8.01 item 9.01

Larimar Therapeutics posts updated investor presentation; no financial results disclosed

Company posted an updated slide presentation on its website on August 14, 2023 for use in investor meetings.
August 10, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Larimar Therapeutics Q2 net loss $8.4M; FDA clears 50 mg cohort and OLE trial for CTI-1601 in FA

Net loss of $8.4M (-$0.19/share) vs $8.7M in Q2 2022; cash $104.2M, runway into Q4 2024.
July 25, 2023, 7:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

FDA clears Larimar's Phase 2 CTI-1601 trial to proceed to 50 mg cohort and OLE trial

FDA cleared Phase 2 dose exploration trial to proceed to 50 mg cohort; dosed daily for 14 days then every other day to day 28.
July 17, 2023, 7:59 PM ET leadership materiality 0.55 neutral item 8.01 item 9.01

Larimar Therapeutics appoints Russell Clayton as CMO, 180K stock option inducement grant

Russell 'Rusty' Clayton appointed Chief Medical Officer effective July 17, 2023, succeeding Nancy M. Ruiz (retiring).
June 1, 2023, 7:59 PM ET other material materiality 0.10 neutral item 8.01 item 9.01

Larimar Therapeutics posts updated corporate presentation for investor meetings

Updated slide presentation posted on company website on June 1, 2023.
May 15, 2023, 7:59 PM ET other material materiality 0.85 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Larimar Phase 2 trial shows frataxin increases in skin and buccal cells; Q1 net loss $6.5M

Median placebo-adjusted frataxin increase from baseline: 3.5 pg/µg in skin, 0.9 pg/µg in buccal cells at day 14.
May 12, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Larimar Therapeutics stockholders elect three Class III directors at 2023 annual meeting

Elected Frank Thomas, Carole S. Ben-Maimon, and Joseph Truitt as Class III directors until 2026.
April 6, 2023, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Director Peter Barrett to resign from Larimar Therapeutics Board effective May 9, 2023

Peter Barrett, Ph.D., resigned from the Board, effective May 9, 2023, the date of the 2023 Annual Meeting.

Executive changes

Appointed

Jeffrey W. Sherman

Class I Director

LRMR · Larimar Therapeutics, Inc.

Effective: 2023-10-03
Filed: October 3, 2023, 7:59 PM ET

On October 3, 2023 (the “ Appointment Date ”), the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”) increased the size of the Board from five to six members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Jeffrey W. Sherman, MD, FACP to serve as a Class I director, with an initial term expiring at the Company’s 2024 Annual Meeting of Stockholders, and a member of the Nominating and Corporate Governance Committee.

Departed

Peter Barrett

Director

LRMR · Larimar Therapeutics, Inc.

Effective: 2023-05-09
Filed: April 6, 2023, 7:59 PM ET

On April 3, 2023, Peter Barrett, Ph.D., a member of the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”), tendered his resignation from the Board to be effective as of May 9, 2023, the date of the Company’s 2023 Annual Meeting of Stockholders.

Departed

Thomas O. Daniel

Class II director

LRMR · Larimar Therapeutics, Inc.

Filed: April 11, 2022, 7:59 PM ET

On April 6, 2022, Thomas O. Daniel, Ph.D., a member of the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”), notified the Company that he will not stand for re-election as a Class II director at the Company’s 2022 Annual Meeting of Stockholders (the “ Annual Meeting ”), and therefore, will no longer serve as a director of the Company or on any committee of the Board, effective as of the conclusion of the Annual Meeting.

Earnings & guidance

2025-Q3 EPS reported -$1.50 vs consensus -$0.41 ▼ miss (-264.0%) filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.62 · Most common event other_material

21 positive 1 negative 28 neutral

source · LRMR on sec.gov